Veppanu (vepdegestrant)
Rigel Pharmaceuticals (RIGL)
ApprovedMay 1, 2026
Marketer take
An oral ER degrader for ESR1-mutated breast cancer after endocrine therapy, competing with Orserdu and AstraZeneca's Etcamah, so ESR1 testing and oncologist sequencing decisions are the battleground.
- Sponsor company
- Rigel Pharmaceuticals (RIGL)
- Indication
- To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Therapeutic area
- Oncology
- Event
- FDA approval
- Date
- May 1, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?